# Clinical trial results:
# A study to assess the acceptability/swallowability of DRV-containing FDC tablets in HIV-1 infected adolescents, using matching placebo tablets

## Summary

| | |
|---|---|
| EudraCT number | 2016-003016-12 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 27 May 2017 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 21 March 2019 |
| First version publication date | 21 March 2019 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | TMC114FD2HTX1003 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02993237 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Janssen Research & Development LLC |
| Sponsor organisation address | Archimedesweg 29, Leiden, Netherlands, 2333CM |
| Public contact | Clinical Registry group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Clinical Registry group, Janssen Research & Development LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMEA-001280-PIP01-12, EMEA-001825-PIP01-15 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 27 May 2017 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 27 May 2017 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The primary objective is to assess the acceptability of swallowing the Darunavir/cobicistat (DRV/COBI) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets, using matching placebo tablets, in a human immunodeficiency virus (HIV-1) infected adolescent subjects.

Protection of trial subjects:

Safety and tolerability was evaluated throughout the study from signing of the Informed Consent Form (ICF)/Assent Form onwards until the last study-related activity.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 23 January 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | United States: 27 |
| Worldwide total number of subjects | 27 |
| EEA total number of subjects | 0 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 27 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

In total, 27 subjects were enrolled in the study and all completed the study as planned, by taking the reference placebo tablet, followed by the DRV/COBI placebo or D/C/F/TAF FDC placebo tablet.

### Period 1

| | |
|---|---|
| Period 1 title | Period 1 (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | D/C/F/TAF FDC placebo followed by DRV/COBI FDC placebo |

Arm description:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 1) and 1 placebo tablet matching the DRV/COBI FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | D/C/F/TAF-FDC Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC on Day 1.

| | |
|---|---|
| Investigational medicinal product name | DRV/COBI-FDC Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC on Day 1.

| | |
|---|---|
| **Arm title** | DRV/COBI FDC Placebo followed by D/C/F/TAF FDC Placebo |

Arm description:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC (Intake 1) and 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | DRV/COBI-FDC Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC on Day 1.

| | |
|---|---|
| Investigational medicinal product name | D/C/F/TAF-FDC Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC on Day 1.

| **Number of subjects in period 1** | D/C/F/TAF FDC placebo followed by DRV/COBI FDC placebo | DRV/COBI FDC Placebo followed by D/C/F/TAF FDC Placebo |
|---|---|---|
| Started | 12 | 15 |
| Completed | 12 | 15 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | D/C/F/TAF FDC placebo followed by DRV/COBI FDC placebo |
| Reporting group description: | |
| Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 1) and 1 placebo tablet matching the DRV/COBI FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes. | |
| Reporting group title | DRV/COBI FDC Placebo followed by D/C/F/TAF FDC Placebo |
| Reporting group description: | |
| Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC (Intake 1) and 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes. | |

| **Reporting group values** | D/C/F/TAF FDC placebo followed by DRV/COBI FDC placebo | DRV/COBI FDC Placebo followed by D/C/F/TAF FDC Placebo | Total |
|---|---|---|---|
| Number of subjects | 12 | 15 | 27 |
| Age Categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 12 | 15 | 27 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous<br>Units: years | | | |
| arithmetic mean | 14.3 | 15.1 | |
| standard deviation | ± 1.60 | ± 1.62 | - |
| Gender Categorical<br>Units: Subjects | | | |
| Female | 6 | 7 | 13 |
| Male | 6 | 8 | 14 |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | D/C/F/TAF FDC placebo followed by DRV/COBI FDC placebo |

Reporting group description:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 1) and 1 placebo tablet matching the DRV/COBI FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| | |
|---|---|
| Reporting group title | DRV/COBI FDC Placebo followed by D/C/F/TAF FDC Placebo |

Reporting group description:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC (Intake 1) and 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| | |
|---|---|
| Subject analysis set title | D/C/F/TAF-FDC Placebo |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.

| | |
|---|---|
| Subject analysis set title | DRV/COBI-FDC Placebo |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC.

### Primary: Acceptability of Swallowing Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus (HIV)-1 Infected Adolescent Subjects

| | |
|---|---|
| End point title | Acceptability of Swallowing Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus (HIV)-1 Infected Adolescent Subjects[1] |

End point description:

Swallowability was assessed based on a 7-point questionnaire indicating how difficult/easy it was to swallow the tablet, ranging from "very difficult" to "very easy". The acceptability proportion is obtained by a dichotomization of the acceptability/swallowability scale, i.e. 'slightly difficult' or worse versus 'neither difficult nor easy' or better. The intent-to-treat (ITT) population included all the subjects who were randomized and received at least 1 dose of treatment subsequent to randomization in the study.

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Day 1

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only descriptive statistical analysis was performed for this outcome measure.

| End point values | D/C/F/TAF-FDC Placebo | DRV/COBI-FDC Placebo | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 27 | 27 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| Acceptable | 92.6 (75.7 to 99.1) | 100 (87.2 to 100) | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Acceptability of Daily Intake of the FDC Tablets, by HIV-1 Infected Adolescent Subjects

| End point title | Acceptability of Daily Intake of the FDC Tablets, by HIV-1 Infected Adolescent Subjects |
|---|---|

End point description:

Acceptability for long term daily use will be assessed based on a 3-point questionnaire, 'not acceptable', 'acceptable', or 'good to take'. The ITT population included all the subjects who were randomized and received at least 1 dose of treatment subsequent to randomization in the study.

| End point type | Secondary |
|---|---|

End point timeframe:

Day 1

| **End point values** | D/C/F/TAF-FDC Placebo | DRV/COBI-FDC Placebo | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 27 | 27 | | |
| Units: subjects | | | | |
| Good to take | 14 | 15 | | |
| acceptable | 11 | 12 | | |
| not acceptable | 2 | 0 | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information[1]

Timeframe for reporting adverse events:

22 Days

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | v20.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | D/C/F/TAF-FDC placebo |

Reporting group description:

Subjects received 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 1) and 1 placebo tablet matching the DRV/COBI FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| | |
|---|---|
| Reporting group title | DRV/COBI-FDC Placebo |

Reporting group description:

Subjects received 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC (Intake 1) and 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC (Intake 2) on Day 1. Both the intakes were separated by at least 30 minutes.

| Serious adverse events | D/C/F/TAF-FDC placebo | DRV/COBI-FDC Placebo | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 15 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | D/C/F/TAF-FDC placebo | DRV/COBI-FDC Placebo | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 12 (0.00%) | 0 / 15 (0.00%) | |

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No adverse events were observed for this study.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported